Advertisement
BMY or MRK or NVS
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. Merck & Co. (MRK) vs. Novartis (NVS) Stock Comparison
Key Takeaways
- Divergent momentum: MRK has shown the strongest relative performance in 2026, while NVS has recently come under significant selling pressure after two late-stage trial setbacks.
- Value versus growth: BMY trades at a lower earnings multiple and higher dividend yield, positioning it as an income-oriented option among the three.
- Patent-cliff exposure: All three companies face the loss of exclusivity on key blockbusters, though the timing and scale differ materially.
- Pipeline risk is real: Recent clinical trial outcomes have driven sharp swings in NVS, underscoring how binary data readouts affect sentiment.
- Sentiment gap: MRK is currently viewed as a momentum leader, BMY as a defensively valued turnaround story, and NVS as a company under investor scrutiny.
Introduction
Pharmaceutical giants BMY, MRK, and NVS operate in the same broad sector but tell sharply different stories in the current market environment. Comparing them highlights how business mix, pipeline momentum, and patent-cliff timing can produce very different risk-reward profiles even among established drugmakers. This stock comparison is relevant to investors weighing a diversified large-cap pharmaceutical allocation, income-focused buyers evaluating dividend yields, and traders tracking relative performance and sentiment shifts across the sector. Understanding each company's recent market positioning helps clarify which factors are currently driving these three names in opposing directions.
BMY Overview and Recent Performance
BMY (Bristol-Myers Squibb) is a global biopharmaceutical company focused on oncology, cardiovascular, hematology, and immunology. Its portfolio includes the immuno-oncology therapy Opdivo and cell therapies known as CAR-T (chimeric antigen receptor T-cell) treatments, alongside established franchises facing patent pressures. In recent weeks, the stock has pulled back from earlier highs, trading toward the lower end of its 52-week range and reflecting a more cautious sentiment after a strong prior run. The company carries a relatively low price-to-earnings (P/E) ratio of roughly 13 times and a dividend yield near 4%, which attracts income-oriented investors. Market positioning has been shaped by efforts to offset declining legacy-drug revenue with newer launches, and near-term price behavior suggests investors are weighing those growth drivers against the erosion of older blockbusters.
MRK Overview and Recent Performance
MRK (Merck & Co., Inc.) is a diversified pharmaceutical and vaccine maker whose oncology franchise, led by Keytruda, anchors its revenue base alongside vaccines and animal health. In recent months, the stock has climbed sharply and touched new 52-week highs, supported by positive late-stage data in personalized cancer therapy with Moderna, new product approvals, and acquisition-driven pipeline expansion. Investors have responded favorably to management's emphasis on diversification ahead of Keytruda's expected loss of exclusivity later this decade. However, a recent European court ruling temporarily halting sales of its subcutaneous Keytruda formulation in certain markets has added a layer of uncertainty. Overall, MRK's relative performance has been the strongest of the three, though its valuation now reflects a meaningful growth premium.
NVS Overview and Recent Performance
NVS (Novartis AG) is a Swiss pharmaceutical company concentrated in innovative medicines across oncology, neuroscience, immunology, and cardiovascular-renal-metabolic diseases. Its growth drivers include Kisqali, Kesimpta, Pluvicto, Leqvio, and Scemblix, which have posted strong double-digit sales growth and helped offset generic erosion of older drugs such as Entresto. Recent weeks, however, have been turbulent. Two late-stage trial failures—including the Avidity-acquired del-desiran in myotonic dystrophy—triggered a sharp single-day decline and the stock's worst weekly performance in years. A prominent shareholder subsequently called for board-level changes, intensifying scrutiny of the company's acquisition strategy. This has left NVS trading roughly flat for the year despite otherwise solid underlying commercial momentum.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that collectively monitor and trade thousands of different tickers across varied strategies, timeframes, and risk profiles. Because conditions change quickly, only the best-performing and most suitable robots for the current market environment earn a place in the curated Trending AI Robots section. These bots differ in trading style, holding period, historical performance, and the specific set of tickers they trade, giving users a way to observe data-driven approaches rather than relying on emotion. Traders and investors can browse this selection to see which algorithmic strategies are currently aligned with prevailing market dynamics. Visit the Trending AI Robots page to explore the featured bots and evaluate their statistics for yourself.
Head-to-Head Comparison
The three companies diverge across several dimensions. MRK currently offers the clearest momentum and a richer pipeline narrative but trades at a higher valuation, raising sensitivity to any disappointment. BMY presents a lower-valuation, higher-yield profile, making it more defensive on paper, yet it remains exposed to patent erosion across several established products. NVS combines strong commercial growth drivers with recent clinical-setback risk, creating a wider range of potential outcomes. Sector exposure also differs: MRK leans heavily on oncology and vaccines, BMY on oncology and cardiovascular, and NVS across multiple therapeutic areas with a notable neuroscience footprint. These contrasts mean the three names rarely move in lockstep, offering diversification benefits but requiring careful attention to each company's specific catalysts and risks.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative positioning, and catalyst profile, Tickeron's AI would likely favor MRK among the three at present. Its sustained upward trend, supportive pipeline news flow, and stronger market positioning contrast with BMY's softer recent momentum and NVS's volatility from clinical trial outcomes. That said, the preference is probabilistic rather than definitive, and MRK's elevated valuation introduces downside sensitivity if catalysts stall. The assessment reflects current trend and stability signals rather than a permanent ranking, and it could shift as new data, earnings, and regulatory developments emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BMY in downward trend: price dove below 50-day moving average on October 23, 2026
BMY moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend. In 35 of 44 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 80%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 10-day moving average for BMY crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
BMY broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BMY entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BMY's RSI Indicator exited the oversold zone, 14 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 47%.
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on BMY as a result. In 46 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 51%.
The Moving Average Convergence Divergence (MACD) for BMY just turned positive on October 16, 2026. Looking at past instances where BMY's MACD turned positive, the stock continued to rise in 29 of 50 cases over the following month. The odds of a continued upward trend are 58%.
Following a +6.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in 174 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 30 (best 1 - 100 worst), indicating outstanding price growth. BMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 69 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.627) is normal, around the industry mean (-2.730). P/E Ratio (13.482) is within average values for comparable stocks, (21.349). BMY's Projected Growth (PEG Ratio) (17.786) is slightly higher than the industry average of (5.738). Dividend Yield (0.041) settles around the average of (0.040) among similar stocks. P/S Ratio (2.642) is also within normal values, averaging (4.033).
MRK sees its Stochastic Oscillator climbs out of oversold territory
On October 09, 2026, the Stochastic Oscillator for MRK moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 52 instances where the indicator left the oversold zone. In 33 of the 52 cases the stock moved higher in the following days. This puts the odds of a move higher at over 63%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for MRK just turned positive on October 20, 2026. Looking at past instances where MRK's MACD turned positive, the stock continued to rise in 27 of 51 cases over the following month. The odds of a continued upward trend are 53%.
Following a +4.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in 192 of 339 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
MRK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRK as a result. In 47 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 55%.
MRK moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MRK crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 29 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. MRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 79 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.547) is normal, around the industry mean (-2.730). MRK's P/E Ratio (115.294) is considerably higher than the industry average of (21.349). Projected Growth (PEG Ratio) (2.716) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.040) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (4.033).
NVS's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for NVS turned positive on September 24, 2026. Looking at past instances where NVS's MACD turned positive, the stock continued to rise in 32 of 45 cases over the following month. The odds of a continued upward trend are 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on NVS as a result. In 42 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 52%.
NVS moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for NVS crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +1.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVS advanced for three days, in 184 of 336 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
The Aroon Indicator entered an Uptrend today. In 158 of 318 cases where NVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 50%.
Bearish Trend Analysis
The 10-day RSI Indicator for NVS moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 20 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 54%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for NVS moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 45%.
NVS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 7 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.914) is normal, around the industry mean (-2.730). P/E Ratio (22.657) is within average values for comparable stocks, (21.349). Projected Growth (PEG Ratio) (3.441) is also within normal values, averaging (5.738). NVS has a moderately high Dividend Yield (0.125) as compared to the industry average of (0.040). P/S Ratio (4.715) is also within normal values, averaging (4.033).
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. NVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
BMY | MRK | NVS | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 70 | 75 | 17 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 89 Overvalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 72 | 29 | 7 | |
SMR RATING 1..100 | 22 | 79 | 33 | |
PRICE GROWTH RATING 1..100 | 30 | 39 | 43 | |
P/E GROWTH RATING 1..100 | 69 | 1 | 19 | |
SEASONALITY SCORE 1..100 | 75 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (12) in the Pharmaceuticals Major industry is significantly better than the same rating for MRK (89) and is significantly better than the same rating for BMY (94). This means that NVS's stock grew significantly faster than MRK’s and significantly faster than BMY’s over the last 12 months.
NVS's Profit vs Risk Rating (7) in the Pharmaceuticals Major industry is in the same range as MRK (29) and is somewhat better than the same rating for BMY (72). This means that NVS's stock grew similarly to MRK’s and somewhat faster than BMY’s over the last 12 months.
BMY's SMR Rating (22) in the Pharmaceuticals Major industry is in the same range as NVS (33) and is somewhat better than the same rating for MRK (79). This means that BMY's stock grew similarly to NVS’s and somewhat faster than MRK’s over the last 12 months.
BMY's Price Growth Rating (30) in the Pharmaceuticals Major industry is in the same range as MRK (39) and is in the same range as NVS (43). This means that BMY's stock grew similarly to MRK’s and similarly to NVS’s over the last 12 months.
MRK's P/E Growth Rating (1) in the Pharmaceuticals Major industry is in the same range as NVS (19) and is significantly better than the same rating for BMY (69). This means that MRK's stock grew similarly to NVS’s and significantly faster than BMY’s over the last 12 months.
| BMY | MRK | NVS | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 47% | N/A | 2 days ago 54% |
| Stochastic ODDS (%) | 2 days ago 54% | 2 days ago 63% | 2 days ago 48% |
| Momentum ODDS (%) | 2 days ago 51% | 2 days ago 55% | 2 days ago 52% |
| MACD ODDS (%) | 2 days ago 58% | 2 days ago 53% | 2 days ago 71% |
| TrendWeek ODDS (%) | 2 days ago 56% | 2 days ago 49% | 2 days ago 55% |
| TrendMonth ODDS (%) | 2 days ago 58% | 2 days ago 42% | 2 days ago 51% |
| Advances ODDS (%) | 10 days ago 56% | 4 days ago 57% | 3 days ago 55% |
| Declines ODDS (%) | 6 days ago 54% | 2 days ago 51% | 19 days ago 45% |
| BollingerBands ODDS (%) | 2 days ago 55% | 2 days ago 60% | 2 days ago 35% |
| Aroon ODDS (%) | 2 days ago 52% | N/A | 2 days ago 50% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 2 FA rating(s) are green while MRK’s FA Score has 2 green FA rating(s), and NVS’s FA Score reflects 4 green FA rating(s).
- BMY’s FA Score: 2 green, 3 red.
- MRK’s FA Score: 2 green, 3 red.
- NVS’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 4 TA indicator(s) are bullish while MRK’s TA Score has 4 bullish TA indicator(s), and NVS’s TA Score reflects 6 bullish TA indicator(s).
- BMY’s TA Score: 4 bullish, 6 bearish.
- MRK’s TA Score: 4 bullish, 4 bearish.
- NVS’s TA Score: 6 bullish, 5 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а +2.90% price change this week, while MRK (@Pharmaceuticals: Major) price change was -0.47% , and NVS (@Pharmaceuticals: Major) price fluctuated +0.33% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.08%. For the same industry, the average monthly price growth was -4.91%, and the average quarterly price growth was +4.21%.
Reported Earning Dates
BMY is expected to report earnings on Oct 29, 2026.
MRK is expected to report earnings on Oct 29, 2026.
NVS is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.08% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.